doi: 10.2165/00003495-199856003-00001pmid: 9844697
Epidemiology and Prognosis of Peripheral Arterial Occlusive Disease (PAOD)
doi: 10.2165/00003495-199856003-00002pmid: 9844698
Diagnostic and Therapeutic Strategies in Peripheral Arterial Occlusive Disease: Non-Drug Measures
doi: 10.2165/00003495-199856003-00003pmid: 9844699
Pharmacotherapeutic Strategies in Peripheral Arterial Occlusive Disease
doi: 10.2165/00003495-199856003-00004pmid: 9844700
Assessment of the Quality-of-Life Implications of Peripheral Arterial Occlusive Disease
Marquis, P.; Lecasble, M.; Passa, Ph.
doi: 10.2165/00003495-199856003-00005pmid: 9844701
Quality of Life in Patients with PAOD Treated with Ifenprodil Tartrate: Results of the ARTEMIS Study
doi: 10.2165/00003495-199856003-00006pmid: 9844702
Quality of Life and Peripheral Arterial Disease: Perspectives for the Future
Hogezand, Ruud; Verspaget, Hein
doi: 10.2165/00003495-199856030-00001pmid: 9777308
Tumour necrosis factor-α (TNFα) is thought to play a central role in the immunopathology of Crohn's disease, particularly since its levels are raised in all types of cells, tissues and secretory fluids of these patients and in animal models of the disease. In addition, TNFα has been found to modulate a number of different processes within the network of inflammatory reactions and therefore has become a target molecule for intervention studies.
Richardson, Paul; Hawkey, Christopher; Stack, William
doi: 10.2165/00003495-199856030-00002pmid: 9777309
Proton pump inhibitors (PPIs) are drugs which irreversibly inhibit proton pump (H+/K+ ATPase) function and are the most potent gastric acid-suppressing agents in clinical use. There is now a substantial body of evidence showing improved efficacy of PPIs over the histamine H2 receptor antagonists and other drugs in acid-related disorders.
Jackson, Christopher; Williams, H.
doi: 10.2165/00003495-199856030-00003pmid: 9777310
Rheumatoid arthritis is a disease of unknown aetiology characterised by persistent joint swelling, functional disability and increased mortality. No curative therapy exists at present but some therapeutic agents, commonly referred to as disease-modifying drugs, offer the potential for suppression of the inflammatory activity and attenuation of the disease process.
Oxholm, Peter; Prause, Jan; Schiødt, Morten
doi: 10.2165/00003495-199856030-00004pmid: 9777311
The aetiology of Sjögren's syndrome (SS) is unknown, and consequently curative treatments are not available. The immunopathogenesis of SS is partly clarified and immune-regulating drugs (IR) may therefore be of therapeutic value. However, the present understanding of SS is still too unclear to allow an exact and evidence-based algorithm for therapeutic decision making. Rational drug recommendations for the therapy of SS must, therefore, rely mostly on empirical data.
Showing 1 to 10 of 19 Articles